---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125526"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:04:04.350130+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IN8bio Q3 net loss $7.1M; cash $4.0M; closes $11.6M placement; INB-100/200 updates

## Summary
- Net loss of $7.1M ($0.15 per share) vs $7.2M loss ($0.23) in Q3 2023.
- Cash $4.0M at Sept 30; closed Oct private placement for $11.6M net proceeds, extending runway into Q1 2026.
- R&D $3.3M (-13% YoY), G&A $2.7M (-21% YoY); severance charges $1.1M from workforce reduction.
- All AML patients in INB-100 remain in CR; FDA provided registrational path; expansion to ~25 patients planned.
- Suspended INB-400 Phase 2 enrollment for newly diagnosed GBM; monitoring continues at SNO and ASH meetings.

## SEC filing metadata
- accession: 0000950170-24-125526
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000095017024125526/0000950170-24-125526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000095017024125526/inab-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125526
- JSON: https://secwatch.observer/filing/0000950170-24-125526.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.